Tablet formulation for cgrp active compounds
US-2016346214-A1 · Dec 1, 2016 · US
Methods of treating migraine
US12465598B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12465598-B2 |
| Application number | US-202418913072-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 11, 2024 |
| Priority date | Sep 27, 2021 |
| Publication date | Nov 11, 2025 |
| Grant date | Nov 11, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides methods for the treatment of migraine by the administration of atogepant or a pharmaceutically acceptable salt thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1 . A method for the preventive treatment of migraine in a patient having severe renal impairment or end stage renal disease, the method comprising orally administering atogepant at the therapeutically effective amount of 10 mg once daily to the patient, wherein the patient's migraines are safely and effectively treated. 2 . The method according to claim 1 , wherein the migraine is episodic migraine. 3 . The method according to claim 1 , wherein the patient has severe renal impairment. 4 . The method according to claim 1 , wherein the patient has end stage renal disease. 5 . The method according to claim 1 , wherein the patient is an adult patient.
Assignees
Inventors
Classifications
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title
Antimigraine agents · CPC title
1,3-Diazoles · CPC title
Indoles, e.g. pindolol · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12465598B2 cover?
- The present disclosure provides methods for the treatment of migraine by the administration of atogepant or a pharmaceutically acceptable salt thereof.
- Who is the assignee on this patent?
- Allergan Pharmaceuticals Int Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4375. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).